A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as mono- or add on therapy, in Patients with Idiopathic Pulmonary Fibrosis (IPF)

Status	Active
Effective start/end date	12/09/22 → 26/09/25

Project Details